• P Bossi, J Cabane, J Ninet, R Dhote, T Hanslik, O Chosidow, C Jouan-Flahault, M H Horellou, F Leynadier, E Liozon, J Pouchot, J P Robin, F Sanderson, A Schaeffer, D Sicard, F Staikowsky, B Wechsler, and R Zittoun.
• Hospital Saint Antoine, Paris, France.
• Am. J. Med. 1998 Nov 1; 105 (5): 400-8.

BackgroundAcquired hemophilia is a rare disease caused by the development of auto-antibodies against factor VIII.Subjects And MethodsWe studied the characteristics and outcomes of 34 patients (19 women and 15 men) with acquired hemophilia from 1980 to 1997.ResultsThe mean age of the patients was 61 years (range, 22-93 years). An underlying disease was observed in 18 (53%) patients: 5 patients had cancer, 4 an autoimmune disorder, 2 a dermatologic disorder, 3 asthma, 3 were postpartum, and 1 had an adverse reaction to ampicillin. Factor VIII level was <5% in 30 (90%) patients; factor VIII antibodies were elevated (>10 Bethesda units) in 23 (69%) patients. Bleeding requiring transfusions was reported in 25 (75%) patients. Human factor VIII was given to 14 patients and porcine factor VIII to 5. Six patients received prothrombin complex concentrates and one desmopressin. Several immunosuppressive treatments were used, mainly corticosteroids, cyclophosphamide, and intravenous immunoglobulin. Bleeding stopped in all but one patient within 2 weeks. Most patients achieved complete remission, although two relapses were observed subsequently.ConclusionThis large study helps to clarify the presentation and clinical course of acquired hemophilia. Prospective studies are needed to determine the efficacy of treatment.

13 keywords...

hide…